undamentalytics Newsletter
Sign in

Assembly Biosciences, Inc. (ASMB) stock

Add to watchlist

Add holding +

NASDAQ: ASMB Nasdaq Biotechnology

B Fundamentals grade

Assembly Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$15

Valuation models combined (2)

Base case. Range ~$5.2–$18. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Assembly Biosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 5 sales by directors and officers, last 12 monthsInsider trades
  • Funds66 adding, 31 cuttingOf 28 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Assembly Biosciences files

Where Assembly Biosciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $75m, up 125.1% on a year earlier, faster than the 121.1% growth a quarter earlier. That growth ranks 24 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -51.5% from -168.0% a year earlier. Operating margin widened to -11.8% from -130.9%. The diluted share count is up 50.8% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $10.10 a share, against a share price of $21.22.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Assembly Biosciences, Inc.'s trailing-twelve-month revenue grew 125.1% year on year, with a free-cash-flow margin of -51.5%. Where it stands out: days sales outstanding of 4 days ranks 1 of 100 biotechnology companies we cover. Where it lags: change in share count of 50.8% ranks 144 of 156 biotechnology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 310% year over year while revenue grew 125% — the balance sheet is expanding 184 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 125.1% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 4.0 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 119.2 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -11.8%: costs exceed revenue.
  • Burning cash. Free cash flow was -51.5% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 50.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 59% and a beta of 1.3 against the S&P 500.
  • Heavily shorted. 19.0% of the shares available to trade are sold short (8.3 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.20 against an average estimate of -$0.67: beat by 70.2%
Revenue
$13m, up 38.9% on a year earlier

Assembly Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.1%
  • 1 week-0.8%
  • 1 month-13.4%
  • This year-42.6%
  • 1 year-37.2%
  • 5 years-49.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$74.8M
Operating margin
-11.8%
Net margin
-0.1%
EPS (TTM, diluted)
$-0.00

Growth

Revenue growth
+125.1%
Change in growth rate
+4.0 pts
Share count change
+50.8%

Cash

Free cash flow (TTM)
-$38.6M
FCF margin
-51.5%
Stock pay % of revenue
8.9%

Earnings

Last results
May 7, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Deal

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Assembly Biosciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Assembly Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.16 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$18 ~$17–$19 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.2 ~$5.4–$20 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$15 ~$5.2–$18 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Assembly Biosciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025
Share price$145.80$543.00$271.44$245.52$72.60$27.96$15.60$9.84$15.78$34.01
Market value$209m$803m$516m$537m$214m$101m$63m$45m$95m$381m
+ Net debt (− = net cash)−$29m−$82m−$41m−$47m−$59m−$46m−$52m−$20m−$38m−$58m
Enterprise value$181m$721m$474m$491m$155m$55m$11m$25m$56m$323m
Multiples
Price / sales —89.1x34.8x33.7x2.7x16.1x—6.3x3.3x5.3x
Price / earnings ——————————
Price / free cash flow —n/m—————2.0x——
EV / EBITDA ——————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

10 /100

Weak moat

How hard Assembly Biosciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -40.3% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -183.1%; its worst year was -672.1%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 6 years, at a median -119.4% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 496.3% over five years; stock-based pay has been a median 23.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.12 +79% $63m −12%
Next −$2.57 −2086% $34m −46%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −184.1% on 90 days ago. In the last 30 days, 2 analysts raised Assembly Biosciences, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Assembly Biosciences, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.14 Current fiscal year, 60 days ago: $0.42 Current fiscal year, 30 days ago: −$0.12 Current fiscal year, 7 days ago: −$0.12 Current fiscal year, Now: −$0.12 −$0.12 Next fiscal year, 90 days ago: −$2.10 Next fiscal year, 60 days ago: −$1.89 Next fiscal year, 30 days ago: −$2.57 Next fiscal year, 7 days ago: −$2.57 Next fiscal year, Now: −$2.57 −$2.57

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.14−$2.10
60 days ago $0.42−$1.89
30 days ago −$0.12−$2.57
7 days ago −$0.12−$2.57
Now −$0.12−$2.57

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.67 −$0.20 +70.2%
Mar 2026 −$0.64 −$0.54 +15.2%
Dec 2025 −$0.85 $2.48 +392.9%
Sept 2025 −$0.65 −$0.72 −10.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, May 7, 2026

No numeric guidance in Assembly Biosciences, Inc.'s latest earnings release (filed May 7, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202655
  3. Aug 202644

Counts of recommendations published by analysts covering Assembly Biosciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
19.0%
of tradable shares
Days to cover
8.29
at average volume
Short interest, 1 month
+39%
to October 15, 2026
Held by institutions
70%
of shares
Held by insiders
27.7%
of shares
Employees
73
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ASMB−62%−44%−37%+60%+116%−43%
Industry peers (median)−35%−57%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ASMB17%25%33%67%58%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ASMB−68%−56%−63%−31%−53%−47%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from March 14, 2018 to November 21, 2023. Getting back needed a 9771% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$19.51 – $38.50
From 52-week high
−49.3%
vs 50-day average
−24.5%
vs 200-day average
−28.1%
Volatility (1 year)
59%
Beta vs S&P 500
1.32

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±4.8%
After a week
9 up, 3 down
typical move ±9.9%
After a month
7 up, 5 down
typical move ±15.2%
Results releasedNext dayS&P 500 next day5 days21 days
May 7, 2026 −5.2% +0.5% −3.4% −28.1%
March 19, 2026 +3.4% −1.7% +4.9% +2.2%
November 10, 2025 +6.2% +1.8% +16.4% +15.0%
August 6, 2025 +12.5% +0.7% +31.2% +26.3%
May 8, 2025 −1.4% +0.6% +0.7% +29.5%
March 20, 2025 +1.5% −0.3% +0.5% −8.4%
November 7, 2024 +0.8% +1.2% +2.4% +0.3%
August 8, 2024 +3.0% +2.8% +11.3% +31.5%
May 8, 2024 +3.1% +0.6% +15.8% +13.2%
March 28, 2024 −3.6% −0.2% +2.9% −3.6%
November 8, 2023 −15.7% −0.7% −16.9% −14.6%
August 9, 2023 −0.9% −0.6% −12.0% −10.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Assembly Biosciences, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Assembly Biosciences, Inc.
$0 $20M $40M $60M $80M FY20 Q4 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY20 Q4: $79.1M Revenue (TTM), FY23 Q4: $7.2M Revenue (TTM), FY24 Q1: $12.9M Revenue (TTM), FY24 Q2: $21.5M Revenue (TTM), FY24 Q3: $28.3M Revenue (TTM), FY24 Q4: $28.5M Revenue (TTM), FY25 Q1: $32.2M Revenue (TTM), FY25 Q2: $33.2M Revenue (TTM), FY25 Q3: $37.2M Revenue (TTM), FY25 Q4: $72.3M Revenue (TTM), FY26 Q1: $71.1M Revenue (TTM), FY26 Q2: $74.8M $74.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY20 Q4 $79.1M
FY23 Q4 $7.2M
FY24 Q1 $12.9M
FY24 Q2 $21.5M
FY24 Q3 $28.3M
FY24 Q4 $28.5M
FY25 Q1 $32.2M
FY25 Q2 $33.2M
FY25 Q3 $37.2M
FY25 Q4 $72.3M
FY26 Q1 $71.1M
FY26 Q2 $74.8M
Revenue growth, TTM YoY Assembly Biosciences, Inc.
0% 200% 400% 600% FY19 Q4 FY20 Q3 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY19 Q4: 7.8% Revenue growth, TTM YoY, FY20 Q1: 6.8% Revenue growth, TTM YoY, FY20 Q2: 250.0% Revenue growth, TTM YoY, FY20 Q3: 454.8% Revenue growth, TTM YoY, FY20 Q4: 395.6% Revenue growth, TTM YoY, FY24 Q4: 298.2% Revenue growth, TTM YoY, FY25 Q1: 148.3% Revenue growth, TTM YoY, FY25 Q2: 54.8% Revenue growth, TTM YoY, FY25 Q3: 31.3% Revenue growth, TTM YoY, FY25 Q4: 153.5% Revenue growth, TTM YoY, FY26 Q1: 121.1% Revenue growth, TTM YoY, FY26 Q2: 125.1% 125.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY19 Q4 7.8%
FY20 Q1 6.8%
FY20 Q2 250.0%
FY20 Q3 454.8%
FY20 Q4 395.6%
FY24 Q4 298.2%
FY25 Q1 148.3%
FY25 Q2 54.8%
FY25 Q3 31.3%
FY25 Q4 153.5%
FY26 Q1 121.1%
FY26 Q2 125.1%
Operating margin (TTM) Assembly Biosciences, Inc.
-1000% -500% 0% FY20 Q4 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY20 Q4: -81.9% Operating margin (TTM), FY23 Q4: -902.5% Operating margin (TTM), FY24 Q1: -431.1% Operating margin (TTM), FY24 Q2: -235.2% Operating margin (TTM), FY24 Q3: -163.9% Operating margin (TTM), FY24 Q4: -159.3% Operating margin (TTM), FY25 Q1: -138.8% Operating margin (TTM), FY25 Q2: -130.9% Operating margin (TTM), FY25 Q3: -116.8% Operating margin (TTM), FY25 Q4: -16.8% Operating margin (TTM), FY26 Q1: -19.1% Operating margin (TTM), FY26 Q2: -11.8% -11.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q4 -81.9%
FY23 Q4 -902.5%
FY24 Q1 -431.1%
FY24 Q2 -235.2%
FY24 Q3 -163.9%
FY24 Q4 -159.3%
FY25 Q1 -138.8%
FY25 Q2 -130.9%
FY25 Q3 -116.8%
FY25 Q4 -16.8%
FY26 Q1 -19.1%
FY26 Q2 -11.8%
FCF margin (TTM) Assembly Biosciences, Inc.
-200% 0% 200% 400% FY20 Q4 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY20 Q4: -80.2% FCF margin (TTM), FY23 Q4: 313.9% FCF margin (TTM), FY24 Q1: 212.7% FCF margin (TTM), FY24 Q2: 112.2% FCF margin (TTM), FY24 Q3: 80.6% FCF margin (TTM), FY24 Q4: -179.3% FCF margin (TTM), FY25 Q1: -174.8% FCF margin (TTM), FY25 Q2: -168.0% FCF margin (TTM), FY25 Q3: -150.0% FCF margin (TTM), FY25 Q4: -56.9% FCF margin (TTM), FY26 Q1: -56.0% FCF margin (TTM), FY26 Q2: -51.5% -51.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY20 Q4 -80.2%
FY23 Q4 313.9%
FY24 Q1 212.7%
FY24 Q2 112.2%
FY24 Q3 80.6%
FY24 Q4 -179.3%
FY25 Q1 -174.8%
FY25 Q2 -168.0%
FY25 Q3 -150.0%
FY25 Q4 -56.9%
FY26 Q1 -56.0%
FY26 Q2 -51.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 9 15 16 79 6 0 7 29 72 75
EBITDA −45 −52 −92 −102 −64 −132 −94 −64 −45 −12 −9
Operating income −45 −52 −93 −103 −65 −133 −94 −65 −45 −12 −9
Net income −44 −43 −91 −98 −62 −130 −93 −61 −40 −6 −0
Diluted EPS −$30.84 −$28.92 −$47.76 −$44.64 −$21.00 −$36.00 −$23.08 −$13.38 −$6.69 −$0.55 —
Growth (year on year)
Revenue — — +64.1% +7.8% +395.6% −92.1% −100.0% — +298.2% +153.5% +125.1%
Margins
EBITDA margin — −576.6% −622.1% −640.3% −81.0% <−999% — −896.2% −158.8% −16.6% −11.6%
Operating margin — −579.1% −626.4% −643.4% −81.9% <−999% — −902.5% −159.3% −16.8% −11.8%
Net margin — −474.7% −613.0% −611.6% −78.6% <−999% — −854.8% −140.9% −8.5% −0.1%
Free-cash-flow margin — 11.0% −441.1% −536.4% −80.2% <−999% — 313.9% −179.3% −56.9% −51.5%
Cash flow
Cash from operations −35 2 −65 −84 −63 −93 −84 23 −51 −41 −38
Capital spending 0 1 0 2 0 3 0 0 0 0 0
Free cash flow −35 1 −65 −86 −63 −96 −85 22 −51 −41 −39
Stock-based pay 5 9 28 21 22 5 7 5 3 5 7
Free cash flow after stock pay −40 −8 −94 −106 −85 −102 −91 17 −54 −46 −45
Balance sheet
Cash 29 82 41 47 59 46 52 20 38 58 32
Total debt 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −29 −82 −41 −47 −59 −46 −52 −20 −38 −58 −32
Diluted shares 1m 1m 2m 2m 3m 4m 4m 5m 6m 11m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $331m
Short-term assets $328mLonger-term assets $3m
What it owes, and who funded it · $331m
Short-term liabilities $23mLonger-term liabilities $2mShareholders' equity $306m
  • Short-term assets cover short-term liabilities $328m of assets due within a year against $23m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $328m short-term assets against $2m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Assembly Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+50.8%
year over year
R&D spending
85.0%
of revenue
Days sales outstanding
4 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ASMB CGEN VRDN WVE ADCT AAPG Median
Revenue, last 12 months $75m $73m $71m $71m $80m $80m $56m
Revenue growth, last 12 months 125.1% 161.1% >999% 202.3% 3.0% −41.4% 12.6%
Revenue growth, 3-year average −3.3% 302.6% 264.4% 20.7% — — 13.7%
Revenue growth, latest quarter 38.9% — 278.7% 72.9% 2.2% — 10.2%
Gross margin — 87.3% 54.5% — — 91.5% 82.9%
Operating margin −11.8% 43.1% −569.7% −320.9% −125.1% — −189.4%
Operating margin, 3-year average −126.0% −255.7% <−999% −256.4% −171.7% — −363.5%
Net margin −0.1% 48.6% −544.1% −296.9% −121.8% −216.5% −169.8%
Cash from operations / revenue −51.4% 43.5% −468.7% −291.9% −128.5% −204.5% −168.0%
Free-cash-flow margin −51.5% 43.1% −471.0% −293.8% −128.5% −209.3% −162.4%
Free-cash-flow margin, 3-year average −35.8% −216.6% <−999% −148.0% −171.3% — −310.0%
Stock pay / revenue 8.9% 2.6% 75.4% 52.8% 12.2% 3.6% 20.0%
Change in share count 50.8% 4.8% 42.0% 20.2% 38.3% 17.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 125.1% 12.6% 35 of 172
Change in growth rate Growth +4.0pp -0.1pp 56 of 172
Operating margin Profitability -11.8% -189.4% 48 of 175
Net margin Profitability -0.1% -157.3% 39 of 180
Free-cash-flow margin Cash generation -51.5% -145.4% 67 of 176
Stock pay as % of revenue Cash generation 8.9% 19.2% 57 of 179
Change in share count Balance sheet 50.8% 7.9% 144 of 156
Days sales outstanding Balance sheet 4 days 75 days 1 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$515M
Institutions reporting
92
Shares held vs prior quarter
▲ 36.2%
Positions opened / closed
32 / 14

Top buyers and sellers, Q2 2026: 66 institutions bought and 31 sold ; the biggest buyer was Paradigm Biocapital Advisors LP (+888K shares) and the biggest seller Stempoint Capital LP (−200K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Gilead Sciences, Inc. $137M 5.0M 26.6% ▲ 10.5%
Farallon Capital Management, L.L.C. $44.1M 1.6M 8.6% ▲ 30.7%
Paradigm Biocapital Advisors LP $42.7M 1.6M 8.3% ▲ 133.6%
Commodore Capital LP $38.9M 1.4M 7.6% ▲ 41.5%
RA Capital Management, L.P. $28M 1.0M 5.4% 0.0%
Jupiter Topco LLC $23.4M 849K 4.5% —
Blackrock, Inc. $21.1M 767K 4.1% ▲ 278.2%
Parkman Healthcare Partners LLC $19.8M 721K 3.8% ▲ 75.4%
Vanguard Capital Management LLC $15.4M 559K 3.0% ▲ 14.0%
Point72 Asset Management, L.P. $12.7M 461K 2.5% ▲ 33.9%
Seven Fleet Capital Management LP $11.9M 433K 2.3% ▲ 671.5%
Millennium Management LLC $8.2M 299K 1.6% ▲ 27.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Assembly Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $14,686 5 trades by 2 insiders · 0% under pre-set plans
Net ▼ $14,686 net selling
Insider Date Trade Shares Price Value
Bjorkquist Jeanette M PFO and PAO June 17, 2026 Sell 29 $23.25 $674
White Nicole S Chief Manufacturing Officer March 30, 2026 Sell 188 $26.65 $5,010
White Nicole S Chief Manufacturing Officer March 30, 2026 Sell 9 $27.49 $247
Bjorkquist Jeanette M PFO and PAO March 30, 2026 Sell 312 $26.65 $8,315
Bjorkquist Jeanette M PFO and PAO March 30, 2026 Sell 16 $27.49 $440

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Assembly Biosciences, Inc. disclosed in the last 12 months; 2 earlier trades on record.

  • Chris Jacobs(R-NY 27):Sale (full), $1,001 - $15,000, traded January 4, 2021, filed February 17, 2021
  • Chris Jacobs(R-NY 27):Purchase, $1,001 - $15,000, traded December 28, 2020, filed February 10, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around August 5, 2026 estimated from the company's past filing pattern, not announced

  • May 7, 2026
  • March 19, 2026
  • November 10, 2025
  • August 6, 2025
  • May 8, 2025
  • March 20, 2025

Recent SEC filings

Data status

When each part of this page on Assembly Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Assembly Biosciences, Inc. in brief

What does Assembly Biosciences, Inc. do?
Assembly Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Assembly Biosciences, Inc.'s stock ticker?
Assembly Biosciences, Inc. trades under the ticker ASMB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Assembly Biosciences, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Assembly Biosciences, Inc. reported revenue of $74.8M, 125.1% higher than a year earlier, according to its SEC filings.
What is Assembly Biosciences, Inc.'s free cash flow?
Assembly Biosciences, Inc.'s free-cash-flow margin is -51.5% of revenue over the trailing twelve months, ranking 67 of the 176 biotechnology companies we cover.
Who are Assembly Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Gilead Sciences, Inc., Farallon Capital Management, L.L.C. and Paradigm Biocapital Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Assembly Biosciences, Inc.'s market cap?
On December 31, 2025, Assembly Biosciences, Inc.'s market capitalisation was about $381M and net debt of -$58.5M. Market figures come from third-party market data and may be delayed.
Who are Assembly Biosciences, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Assembly Biosciences, Inc. are Compugen LTD, Viridian Therapeutics, Inc.\de, Wave Life Sciences, Inc., ADC Therapeutics SA and Ascentage Pharma Group International. The side-by-side comparison below sets their revenue, margins and growth against Assembly Biosciences, Inc.'s.
Are insiders buying or selling Assembly Biosciences, Inc. stock?
Over the last 12 months, Assembly Biosciences, Inc.'s directors and officers reported 0 open-market purchases and 5 sales on Form 4. The insider trading page charts every trade.